This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
glioblastoma
Glioblastoma
Most aggressive primary brain tumor; IDH-wildtype GBM has EGFRvIII amplification (~40%), PTEN loss (~30%), and TERT promoter mutations. Temozolomide + radiotherapy is standard; tumor-treating fields (TTFields) improve OS; MGMT promoter methylation predicts temozolomide benefit.
Entry Metadata
| Field | Value |
|---|---|
| ID | glioblastoma |
| Name | Glioblastoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. · PubMed 15758009
- Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722. · PubMed 24552318